Table 4.
Reasons for drug discontinuation in CKD participants in the AIM-HIGH Trial by randomized treatment arm
| Variables | Placebo, n=174 | Niacin, n=178 | P Value |
|---|---|---|---|
| No. (%) discontinuing | 39 (22) | 68 (38) | 0.001 |
| Reason niacin/placebo discontinued, no. (%) | |||
| Flushing, itching | 6 (3) | 19 (11) | |
| Liver function test abnormality | 0 (0) | 1 (0.6) | |
| Patient request | 18 (10) | 21 (12) | |
| Nonstudy physician request | 5 (3) | 7 (4) | |
| Other clinical reason to discontinue | 7 (4) | 11 (6) | |
| Increased glucose | 2 (1) | 4 (2) | |
| GI symptoms | 1 (0.6) | 4 (2) | |
| Reason not specified | 0 (0) | 1 (0.6) |
AIM-HIGH, Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health; GI, gastrointestinal.